238 related articles for article (PubMed ID: 23561333)
1. A model of study for human cancer: Spontaneous occurring tumors in dogs. Biological features and translation for new anticancer therapies.
Ranieri G; Gadaleta CD; Patruno R; Zizzo N; Daidone MG; Hansson MG; Paradiso A; Ribatti D
Crit Rev Oncol Hematol; 2013 Oct; 88(1):187-97. PubMed ID: 23561333
[TBL] [Abstract][Full Text] [Related]
2. Masitinib (AB1010), from canine tumor model to human clinical development: where we are?
Marech I; Patruno R; Zizzo N; Gadaleta C; Introna M; Zito AF; Gadaleta CD; Ranieri G
Crit Rev Oncol Hematol; 2014 Jul; 91(1):98-111. PubMed ID: 24405856
[TBL] [Abstract][Full Text] [Related]
3. Naturally occurring tumors in dogs as comparative models for cancer therapy research.
Hahn KA; Bravo L; Adams WH; Frazier DL
In Vivo; 1994; 8(1):133-43. PubMed ID: 8054503
[TBL] [Abstract][Full Text] [Related]
4. Clinical, Pathological, and Ethical Considerations for the Conduct of Clinical Trials in Dogs with Naturally Occurring Cancer: A Comparative Approach to Accelerate Translational Drug Development.
Regan D; Garcia K; Thamm D
ILAR J; 2018 Dec; 59(1):99-110. PubMed ID: 30668709
[TBL] [Abstract][Full Text] [Related]
5. Canine tumors: a spontaneous animal model of human carcinogenesis.
Pinho SS; Carvalho S; Cabral J; Reis CA; Gärtner F
Transl Res; 2012 Mar; 159(3):165-72. PubMed ID: 22340765
[TBL] [Abstract][Full Text] [Related]
6. Species-specific properties and translational aspects of canine dendritic cells.
Qeska V; Baumgärtner W; Beineke A
Vet Immunol Immunopathol; 2013 Feb; 151(3-4):181-92. PubMed ID: 23280245
[TBL] [Abstract][Full Text] [Related]
7. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies.
London CA; Hannah AL; Zadovoskaya R; Chien MB; Kollias-Baker C; Rosenberg M; Downing S; Post G; Boucher J; Shenoy N; Mendel DB; McMahon G; Cherrington JM
Clin Cancer Res; 2003 Jul; 9(7):2755-68. PubMed ID: 12855656
[TBL] [Abstract][Full Text] [Related]
8. Pet models in cancer research: general principles.
Porrello A; Cardelli P; Spugnini EP
J Exp Clin Cancer Res; 2004 Jun; 23(2):181-93. PubMed ID: 15354401
[TBL] [Abstract][Full Text] [Related]
9. Oncology of companion animals as a model for humans. an overview of tumor histotypes.
Porrello A; Cardelli P; Spugnini EP
J Exp Clin Cancer Res; 2006 Mar; 25(1):97-105. PubMed ID: 16761625
[TBL] [Abstract][Full Text] [Related]
10. A novel trauma model: naturally occurring canine trauma.
Hall KE; Sharp CR; Adams CR; Beilman G
Shock; 2014 Jan; 41(1):25-32. PubMed ID: 24089005
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer in dogs: comparative and clinical aspects.
Leroy BE; Northrup N
Vet J; 2009 May; 180(2):149-62. PubMed ID: 18786842
[TBL] [Abstract][Full Text] [Related]
12. Naturally occurring cancers in dogs: insights for translational genetics and medicine.
Alvarez CE
ILAR J; 2014; 55(1):16-45. PubMed ID: 24936028
[TBL] [Abstract][Full Text] [Related]
13. The use of naturally occurring cancer in domestic animals for research into human cancer: general considerations and a review of canine skeletal osteosarcoma.
Brodey RS
Yale J Biol Med; 1979; 52(4):345-61. PubMed ID: 115162
[TBL] [Abstract][Full Text] [Related]
14. Telomerase and HER-2/neu as targets of genetic cancer vaccines in dogs.
Peruzzi D; Mesiti G; Ciliberto G; La Monica N; Aurisicchio L
Vaccine; 2010 Feb; 28(5):1201-8. PubMed ID: 19944791
[TBL] [Abstract][Full Text] [Related]
15. The Challenge of Developing New Therapies for Childhood Cancers.
Balis FM
Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
[TBL] [Abstract][Full Text] [Related]
16. Anticancer Drug Development: The Way Forward.
Connors T
Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
[TBL] [Abstract][Full Text] [Related]
17. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision.
London CA; Malpas PB; Wood-Follis SL; Boucher JF; Rusk AW; Rosenberg MP; Henry CJ; Mitchener KL; Klein MK; Hintermeister JG; Bergman PJ; Couto GC; Mauldin GN; Michels GM
Clin Cancer Res; 2009 Jun; 15(11):3856-65. PubMed ID: 19470739
[TBL] [Abstract][Full Text] [Related]
18. Spontaneous and genetically engineered animal models; use in preclinical cancer drug development.
Hansen K; Khanna C
Eur J Cancer; 2004 Apr; 40(6):858-80. PubMed ID: 15120042
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic properties of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumors.
Yancey MF; Merritt DA; Lesman SP; Boucher JF; Michels GM
J Vet Pharmacol Ther; 2010 Apr; 33(2):162-71. PubMed ID: 20444041
[TBL] [Abstract][Full Text] [Related]
20. [Challenges for clinical research on rare tumors in Europe].
Blay JY
Bull Acad Natl Med; 2013 Jan; 197(1):103-21; discussion 121-2. PubMed ID: 24672983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
